CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Heron Therapeutics, Inc. - HRTX CFD

1.81
0.56%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.05
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.024818 %
Charges from full value of position ($-4.72)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.024818%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.002596 %
Charges from full value of position ($0.49)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.002596%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 1.8
Open 1.57
1-Year Change 76.4%
Day's Range 1.57 - 1.81
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Oct 11, 2024 1.81 0.02 1.12% 1.79 1.81 1.39
Oct 10, 2024 1.80 -0.04 -2.17% 1.84 1.89 1.80
Oct 9, 2024 1.84 -0.05 -2.65% 1.89 1.89 1.83
Oct 8, 2024 1.90 -0.02 -1.04% 1.92 1.96 1.88
Oct 7, 2024 1.94 -0.15 -7.18% 2.09 2.12 1.92
Oct 4, 2024 2.11 0.04 1.93% 2.07 2.12 2.03
Oct 3, 2024 2.06 0.00 0.00% 2.06 2.09 2.01
Oct 2, 2024 2.08 0.12 6.12% 1.96 2.12 1.96
Oct 1, 2024 1.98 0.02 1.02% 1.96 1.99 1.92
Sep 30, 2024 1.97 0.01 0.51% 1.96 2.06 1.95
Sep 27, 2024 1.97 -0.09 -4.37% 2.06 2.12 1.96
Sep 26, 2024 2.03 0.12 6.28% 1.91 2.06 1.90
Sep 25, 2024 1.87 -0.10 -5.08% 1.97 1.98 1.85
Sep 24, 2024 1.94 0.00 0.00% 1.94 1.96 1.89
Sep 23, 2024 1.95 -0.10 -4.88% 2.05 2.05 1.92
Sep 20, 2024 2.03 0.04 2.01% 1.99 2.03 1.91
Sep 19, 2024 1.98 0.00 0.00% 1.98 2.08 1.93
Sep 18, 2024 1.92 -0.01 -0.52% 1.93 1.95 1.82
Sep 17, 2024 1.88 0.05 2.73% 1.83 1.94 1.82
Sep 16, 2024 1.80 -0.06 -3.23% 1.86 1.90 1.80

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Heron Therapeutics, Inc. Company profile

About Heron Therapeutics Inc

Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF (HTX-011), HTX-019, and HTX-034. HTX-011 is a dual-acting local anaesthetic that delivers a fixed-dose combination of the local anaesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. HTX-019 is an investigational agent for the prevention of postoperative nausea and vomiting. HTX-034 is a product candidate for postoperative pain management.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Heron Therapeutics Inc revenues decreased 3% to $86.3M. Net loss decreased 3% to $220.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects "Research and development - Balancing va decrease of 39% to $66.4M (expense), Stock-based Compensation in SGA decrease of 24% to $11.8M (expense).

Equity composition

Common Stock $.01 Par, 02/10, 50M auth., 40,143,227 issd. Insiders own 6.70%. IPO: 8/87, 2M shares @ $7.00 by Allen & Co. 2/92, private placement of 1,150,000 units (1 Share + 1 Warrant). 5/01, Name changed from Advanced Polymer Systems, Inc. FY'01 fncls. are restated. 05/07, 1-for-4 reverse stock split. 01/14, 1-for-20 Reverse stock split.

Industry: Biotechnology & Medical Research (NEC)

4242 Campus Point Court, Suite 200
SAN DIEGO
CALIFORNIA 92121
US

News

S&P 500 expected to deliver modest earnings growth in Q3

Earnings growth across the S&P 500 is expected to be modest in Q3, with a projected 4.2% increase in EPS, down from 7.8% in the previous quarter. Information technology, health care, and communication services are poised to drive growth, particularly IT with a forecasted 15% year-over-year EPS increase.

12:40, 11 October 2024

US Core CPI tipped to remain unchanged in September

US inflation expectations are steady, with core CPI projected to remain at 3.2% for September while headline inflation moderates to its lowest level since February 2021. Despite the US Federal Reserve delivering a 50 basis point interest rate cut in September, stronger-than-expected job market data has raised concerns about sustained economic demand and inflation pressures.

07:10, 9 October 2024

RBNZ expected to deliver “jumbo” rate cut

The Reserve Bank of New Zealand is set to cut interest rates during its upcoming meeting, with expectations of either a 25 or 50 basis point reduction. This move follows a 25 basis point cut in August as the RBNZ responded to the country’s recessionary conditions and inflation concerns.

08:48, 8 October 2024

September Non-Farm Payrolls eases fears of US economic slowdown

Markets are reacting with a US Dollar surge and a potential trend reversal, highlighting the impact of robust economic activity outside of monetary policy influences.

07:44, 8 October 2024

Gold's recent story

Last week, we explored the key price drivers of gold, and how they impacted the price of the precious metal this year and last. Now, we’ll bring these factors to life in a chart, showing you ten instances the gold price responded to critical fundamental events, including central bank policies, global economic data, and geopolitical events.

15:36, 7 October 2024

September US Non-Farm Payrolls Preview

Kyle Rodda, Senior Market Analyst at Capital.com, previews the US Non-Farm Payrolls report for September. The article discusses market expectations of a stable labor market with 150,000 new jobs, an unchanged unemployment rate of 4.2%, and steady annual wage growth at 3.8%. It also highlights potential rate cuts by the Federal Reserve, revisions to past payroll data, and the reaction of various markets such as the US Dollar, S&P 500, and gold.

07:59, 2 October 2024

Market of the Month - Gold, an overview

In 2024, gold has been on an upward trajectory, hitting high after high as global markets face ongoing challenges. This precious metal, long seen as a safe haven, has been proving its worth, drawing attention from traders around the world as its bullish surge continues.

06:00, 30 September 2024

People also watch

XRP/USD

0.54 Price
-1.520% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 0.01168

US100

20,229.30 Price
+0.010% 1D Chg, %
Long position overnight fee -0.0248%
Short position overnight fee 0.0026%
Overnight fee time 21:00 (UTC)
Spread 1.8

BTC/USD

62,659.50 Price
-0.630% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Gold

2,644.87 Price
-0.420% 1D Chg, %
Long position overnight fee -0.0174%
Short position overnight fee 0.0092%
Overnight fee time 21:00 (UTC)
Spread 0.30

Still looking for a broker you can trust?

Join the 650,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading